1
|
Nakar C, Shapiro A. Hemophilia A with inhibitor: Immune tolerance induction (ITI) in the mirror of time. Transfus Apher Sci 2019; 58:578-589. [PMID: 31447396 DOI: 10.1016/j.transci.2019.08.008] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Inhibitor (neutralizing antibodies) development remains the most significant complication in patients with severe congenital hemophilia A receiving exogenous factor VIII (FVIII). Although our understanding of the pathophysiology of inhibitor development has advanced, the knowledge gained has not yet translated into a robust decline in incidence, with the overall risk remaining at ∼30%. Immune Tolerance Induction (ITI) is the only current method to successfully eradicate an inhibitor and achieve long-term tolerance. Although current practice utilizes a wide variety of ITI regimens, identification of an optimal regimen has not emerged. Over the last decade, the number of replacement products available in hemophilia has greatly expanded. The cumulative evidence with each product for use in ITI is often lacking. Most recently emicizumab, a humanized monoclonal bi-specific antibody that substitutes for the scaffolding effect of FVIIIa was approved; this agent prevents bleeding in both inhibitor and non-inhibitor patients. The use of emicizumab will bring about a new era in care that will require clinicians to challenge current practice paradigms including use and administration of ITI. This review will summarize the main clinical ITI data and practices for patients with severe congenital hemophilia A with inhibitors (CHAwI) over the last four decades and will highlight current studies in the field, with attention to open questions.
Collapse
Affiliation(s)
- Charles Nakar
- The Indiana Hemophilia and Thrombosis Center (IHTC), Indianapolis, IN, USA.
| | - Amy Shapiro
- The Indiana Hemophilia and Thrombosis Center (IHTC), Indianapolis, IN, USA
| |
Collapse
|
2
|
Ekert H, McVeagh P. ACTIVATED PPSB IN THE TREATMENT OF A PATIENT WITH HAEMOPHILIA AND ANTIBODIES TO FACTOR VIII. Med J Aust 2019. [DOI: 10.5694/j.1326-5377.1975.tb106192.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- Henry Ekert
- Haematology Clinic, Royal Children's HospitalMelbourne
- Haematology Clinic, Royal Children's HospitalParkvilleVic.3052
| | - P. McVeagh
- Haematology Clinic, Royal Children's HospitalMelbourne
| |
Collapse
|
3
|
Stewart AJ, Saint-Remy JM, Ludlam CA. Pathogenesis and Management of Acquired Haemophilia. Hematology 2016; 3:181-92. [DOI: 10.1080/10245332.1998.11746390] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
4
|
Rizza CR. The management of haemophiliacs who have antibodies to factor VIII. SCANDINAVIAN JOURNAL OF HAEMATOLOGY. SUPPLEMENTUM 2009; 40:187-93. [PMID: 6433451 DOI: 10.1111/j.1600-0609.1984.tb02563.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
5
|
Ingram GI, Dykes SR, Creese AL, Mellor P, Swan AV, Kaufert JK, Rizza CR, Spooner RJ, Biggs R. Home treatment in haemophilia: clinical, social and economic advantages. CLINICAL AND LABORATORY HAEMATOLOGY 2008; 1:13-27. [PMID: 535301 DOI: 10.1111/j.1365-2257.1979.tb00586.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Twenty-eight severely affected haemophiliacs were observed for 3 months under treatment as hospital out-patients and for the subsequent 9 months while treating themselves at home. Delay in receiving treatment and financial costs were both clearly reduced by home treatment, the patients recovered from individual bleeds more quickly and reported a greater sense of personal freedom and independence. The amount of treatment required did not materially change and no untoward effects were noted; the use of analgesics tended to be less.
Collapse
|
6
|
Spiegel PC, Stoddard BL. Optimization of factor VIII replacement therapy: can structural studies help in evading antibody inhibitors? Br J Haematol 2002; 119:310-22. [PMID: 12406063 DOI: 10.1046/j.1365-2141.2002.03845.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Affiliation(s)
- P Clint Spiegel
- Graduate Program in Biomolecular Structure and Design, University of Washington, Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle 98109, USA
| | | |
Collapse
|
7
|
Ling M, Duncan EM, Rodgers SE, Somogyi AA, Crabb GA, Street AM, Lloyd JV. Classification of the kinetics of factor VIII inhibitors in haemophilia A: plasma dilution studies are more discriminatory than time-course studies. Br J Haematol 2001; 114:861-7. [PMID: 11564075 DOI: 10.1046/j.1365-2141.2001.03067.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Factor VIII inhibitors have previously been classified as type I or type II using complex experiments that study the time course of inactivation of factor VIII and the effect of varying the antibody concentration. Classification may be important to better understand inhibitor behaviour in vivo. To determine the most reliable method of classifying the kinetics of factor VIII inactivation, we studied 11 patients with haemophilia A, comprising five severe, three mild and three acquired cases, and compared the classification obtained from plasma dilution studies and time-course studies. The plasma dilution studies showed two distinctly different patterns: a steep slope with complete FVIII:C inactivation at high antibody concentrations for type I inhibitors and a FVIII:C plateau with incomplete inactivation for type II inhibitors. Six type I (four severe, one mild and one acquired) and two type II (one mild and one acquired) inhibitors were classified using either plasma samples or purified and concentrated IgG, while the remaining were undetermined owing to insufficient available plasma. In contrast, the time-course studies could not discriminate between these groups. We recommend that plasma dilution studies be used for the classification of in vitro kinetics of factor VIII inhibitors.
Collapse
Affiliation(s)
- M Ling
- Division of Haematology, Institute of Medical and Veterinary Science, Adelaide University, Adelaide, SA, Australia
| | | | | | | | | | | | | |
Collapse
|
8
|
Spiegel PC, Jacquemin M, Saint-Remy JM, Stoddard BL, Pratt KP. Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII. Blood 2001; 98:13-9. [PMID: 11418455 DOI: 10.1182/blood.v98.1.13] [Citation(s) in RCA: 106] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The development of an immune response to infused factor VIII is a complication affecting many patients with hemophilia A. Inhibitor antibodies bind to antigenic determinants on the factor VIII molecule and block its procoagulant activity. A patient-derived inhibitory immunoglobulin G4kappa antibody (BO2C11) produced by an immortalized memory B-lymphocyte cell line interferes with the binding of factor VIII to phospholipid surfaces and to von Willebrand factor. The structure of a Fab fragment derived from this antibody complexed with the factor VIII C2 domain was determined at 2.0 A resolution. The Fab interacts with solvent-exposed basic and hydrophobic side chains that form a membrane-association surface of factor VIII. This atomic resolution structure suggests a variety of amino acid substitutions in the C2 domain of factor VIII that might prevent the binding of anti-C2 inhibitor antibodies without significantly compromising the procoagulant functions of factor VIII.
Collapse
Affiliation(s)
- P C Spiegel
- Graduate Program in Biomolecular Structure and Design, University of Washington, and Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | | | | | | | | |
Collapse
|
9
|
Bossi P, Cabane J, Ninet J, Dhote R, Hanslik T, Chosidow O, Jouan-Flahault C, Horellou MH, Leynadier F, Liozon E, Pouchot J, Robin JP, Sanderson F, Schaeffer A, Sicard D, Staikowsky F, Wechsler B, Zittoun R. Acquired hemophilia due to factor VIII inhibitors in 34 patients. Am J Med 1998; 105:400-8. [PMID: 9831424 DOI: 10.1016/s0002-9343(98)00289-7] [Citation(s) in RCA: 134] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
BACKGROUND Acquired hemophilia is a rare disease caused by the development of auto-antibodies against factor VIII. SUBJECTS AND METHODS We studied the characteristics and outcomes of 34 patients (19 women and 15 men) with acquired hemophilia from 1980 to 1997. RESULTS The mean age of the patients was 61 years (range, 22-93 years). An underlying disease was observed in 18 (53%) patients: 5 patients had cancer, 4 an autoimmune disorder, 2 a dermatologic disorder, 3 asthma, 3 were postpartum, and 1 had an adverse reaction to ampicillin. Factor VIII level was <5% in 30 (90%) patients; factor VIII antibodies were elevated (>10 Bethesda units) in 23 (69%) patients. Bleeding requiring transfusions was reported in 25 (75%) patients. Human factor VIII was given to 14 patients and porcine factor VIII to 5. Six patients received prothrombin complex concentrates and one desmopressin. Several immunosuppressive treatments were used, mainly corticosteroids, cyclophosphamide, and intravenous immunoglobulin. Bleeding stopped in all but one patient within 2 weeks. Most patients achieved complete remission, although two relapses were observed subsequently. CONCLUSION This large study helps to clarify the presentation and clinical course of acquired hemophilia. Prospective studies are needed to determine the efficacy of treatment.
Collapse
Affiliation(s)
- P Bossi
- Hospital Saint Antoine, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Mechanism and Kinetics of Factor VIII Inactivation: Study With an IgG4 Monoclonal Antibody Derived From a Hemophilia A Patient With Inhibitor. Blood 1998. [DOI: 10.1182/blood.v92.2.496] [Citation(s) in RCA: 115] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
AbstractThe development of an immune response towards factor VIII (fVIII) remains a major complication for hemophilia A patients receiving fVIII infusions. The design of a specific therapy to restore unresponsiveness to fVIII has been hampered by the diversity of the anti-fVIII antibody. Molecular analysis of the specific immune response is therefore required. To this end, we have characterized an fVIII-specific human IgG4κ monoclonal antibody (BO2C11) produced by a cell line derived from the memory B-cell repertoire of a hemophilia A patient with inhibitor. BO2C11 recognizes the C2 domain of fVIII and inhibits its binding to both von Willebrand factor (vWF) and phospholipids. It completely inhibits the procoagulant activity of native and activated fVIII, with a specific activity of approximately 7,000 Bethesda units/mg. vWF reduces the rate of fVIII inactivation by BO2C11. The antibody-fVIII association rate constant (kass ∼7.4 × 105M−1 s−1) is eightfold lower than that for vWF-fVIII association, whereas its dissociation rate constant (kdiss ≤1 × 10−5s−1) is 100-fold lower than that for the vWF-fVIII complex, which suggests that BO2C11 almost irreversibly neutralizes fVIII after its dissociation from vWF. BO2C11 is the first human monoclonal anti-fVIII IgG antibody that has been isolated and allows the study of fVIII inactivation at the molecular level.
Collapse
|
11
|
Mechanism and Kinetics of Factor VIII Inactivation: Study With an IgG4 Monoclonal Antibody Derived From a Hemophilia A Patient With Inhibitor. Blood 1998. [DOI: 10.1182/blood.v92.2.496.414k16_496_506] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The development of an immune response towards factor VIII (fVIII) remains a major complication for hemophilia A patients receiving fVIII infusions. The design of a specific therapy to restore unresponsiveness to fVIII has been hampered by the diversity of the anti-fVIII antibody. Molecular analysis of the specific immune response is therefore required. To this end, we have characterized an fVIII-specific human IgG4κ monoclonal antibody (BO2C11) produced by a cell line derived from the memory B-cell repertoire of a hemophilia A patient with inhibitor. BO2C11 recognizes the C2 domain of fVIII and inhibits its binding to both von Willebrand factor (vWF) and phospholipids. It completely inhibits the procoagulant activity of native and activated fVIII, with a specific activity of approximately 7,000 Bethesda units/mg. vWF reduces the rate of fVIII inactivation by BO2C11. The antibody-fVIII association rate constant (kass ∼7.4 × 105M−1 s−1) is eightfold lower than that for vWF-fVIII association, whereas its dissociation rate constant (kdiss ≤1 × 10−5s−1) is 100-fold lower than that for the vWF-fVIII complex, which suggests that BO2C11 almost irreversibly neutralizes fVIII after its dissociation from vWF. BO2C11 is the first human monoclonal anti-fVIII IgG antibody that has been isolated and allows the study of fVIII inactivation at the molecular level.
Collapse
|
12
|
Abstract
Acquired haemophilia is a rare but life-threatening acquired bleeding diathesis caused by autoimmune depletion of factor VIII. This occurs most frequently in elderly patients who lack disease associations. Acquired haemophilia may also arise in association with SLE rheumatoid arthritis, Sjögren's syndrome, other autoimmune conditions, lymphoproliferative malignancy, pregnancy and as a drug reaction. Acquired haemophilia has an equal sex distribution. The aims of treatment are to eliminate the inhibitor by immunosuppression and to treat the bleeding, which is the most common cause of death in patients with acquired haemophilia. The inhibitor is abolished in up to 70% of patients using prednisolone and cyclophosphamide, although other immunosuppressive regimens may also be used. These include azathioprine, vincristine and other cytotoxic agents, high-dose immunoglobulin and cyclosporin A. Bleeding may be controlled using porcine factor VIII or recombinant factor VIIa, although human factor VIII and prothrombin complex concentrates also have a limited role as haemostatic agents in this condition.
Collapse
Affiliation(s)
- C R Hay
- Manchester Haemophilia Comprehensive Care Centre, University Department of Haematology, Manchester Royal Infirmary, UK
| |
Collapse
|
13
|
Affiliation(s)
- A E Morrison
- Department of Haematology, Royal Infirmary, Edinburgh
| | | |
Collapse
|
14
|
Abstract
One patient with an acquired factor VIII inhibitor is reported in which an acute lower intestinal hemorrhage was successfully managed using Desmopressin (DDAVP). The patient initially had a factor VIII level of 10% with a inhibitor titer of 1.9 Bethesda units. Following administration of DDAVP the factor VIII level rose to 86% and there was a decrease in the number and volume of bloody stools. The inhibitor disappeared following treatment with corticosteroids, however the patient ultimately expired due to complications of ischemic colitis. This case and 21 previously reported cases of acquired hemophilia treated with DDAVP are reviewed. The data support a role for DDAVP in the treatment of non life threatening hemorrhage in patients with acquired hemophilia and low titer factor VIII inhibitors (< 5 Bethesda units or factor VIII > or = 5%).
Collapse
Affiliation(s)
- R Mudad
- Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710
| | | |
Collapse
|
15
|
|
16
|
Staikowsky F, Guidet B, Thuaire C. Les inhibiteurs spontanés du facteur antihémophilique A : Données cliniques et biologiques, aspects thérapeutiques. ACTA ACUST UNITED AC 1992. [DOI: 10.1016/s1164-6756(05)80564-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
17
|
Abstract
Spontaneous development of autoantibodies against factor VIII:C (FVIII:C) protein in a nonhemophiliac is a rare but significant clinical occurrence that frequently is associated with life-threatening hemorrhagic complications. These autoantibodies often arise as an epiphenomenon of various disease states that are autoimmune or manifest a component of immune dysfunction. The present symposium reviews the immunochemistry of FVIII:C auto-antibodies and describes ways in which this knowledge has been applied to gain insight into the structure-function relationship of the FVIII:C protein. Also discussed are the etiology and natural history of acquired FVIII:C inhibition as well as evolving approaches to its treatment. Therapeutic options for this condition continue to expand, and choice of the optimal regimen for each patient is based on many considerations, including the level of the inhibitor, the underlying disease state, clinical responses to previous treatment, and degree of antibody interaction with heterologous purified FVIII:C protein. Acquired FVIII:C autoantibodies isolated from nonhemophiliacs are characterized as heterogeneous, noncomplement-fixing, nonprecipitating immunoglobulins directed against functional epitopes (antigenic sites) of FVIII:C in a time- and temperature-dependent manner. The clinical significance of these inhibitors is determined qualitatively by studying in vivo survival of FVIII:C activity with infused replacement materials or quantitatively by laboratory mixing tests that measure the capacity of the inhibitor to neutralize FVIII:C activity. In the United States inhibitor potency is expressed most commonly in Bethesda Units (BU), where 1.0 BU is the reciprocal dilution of patient test plasma, permitting detection of 50% residual FVIII:C activity in a mixture with normal pooled plasma. In Europe, FVIII inhibitors are now often quantitated in New Oxford Units, which are derived from neutralizing-mixing studies of patient test plasma with diluted FVIII concentrate. One Oxford unit is equivalent to approximately 0.83 BU. Although analyses that measure functional inhibition of FVIII:C activity by the autoantibody provide a useful tool to assess clinical efficacy of therapeutic regimens, these assays may not recognize nonactivating antibodies. These immunoglobulins may bind to alternative epitopes and significantly influence plasma clearance, survival times, and circulating levels of infused FVIII:C protein. Finally, this symposium will speculate on the potential application of innovative approaches to inhibitor therapy, based on results from numerous provocative studies on the nature of the human immune response.
Collapse
Affiliation(s)
- C M Kessler
- Department of Medicine, George Washington University School of Medicine, Washington, D.C. 20037
| |
Collapse
|
18
|
Affiliation(s)
- C K Kasper
- School of Medicine, University of Southern California, Los Angeles 90007
| |
Collapse
|
19
|
Jude B, Goudemand J, Jouet JP, Watel A, Caron C, Rouget JP, Bauters F, Cosson A. [Inhibitors of factor VIII in non-hemophilic patients. Biological and therapeutic aspects. Apropos of 3 cases]. Rev Med Interne 1986; 7:377-84. [PMID: 3099358 DOI: 10.1016/s0248-8663(86)80127-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
A coagulation inhibitor of the anti-factor VIII: C type was detected in three non-haemophilic male patients aged 75, 70 and 52 respectively. In all three patients antibody titres were low (less than 12.5 Bethesda units initially, less than 20 units subsequently), and a low but detectable level of factor VIII: C persisted (7 to 12 p. 100 in two patients who had severe haemorrhages and 2.100 in the third one). The 3 inhibitors inactivated factor VIII: C with a complex, type II kinetics (Biggs et al.). Strong doses of anti-haemophilic A fractions were biologically effective in one patient but could not stop severe bleeding. Activated plasma fractions were used successfully on several occasions. Once, moderate and repeated doses of anti-haemophilic A fractions resulted in satisfactory correction of factor VIII: C level, and a minor surgical operation could be performed. An immunosuppressive treatment was administered for 3 weeks to one patient and for 3 months to the other two patients. In all three cases the inhibitor disappeared after 5 to 8 months. In non-haemophilic patients with factor VII: C inhibitor the treatment of haemorrhagic episodes must take into account the severity of bleeding, then the usually complex kinetics of the inhibitor; thus it cannot be a direct copy of the treatment used in haemophiliacs with type I inhibitors.
Collapse
|
20
|
Saba SR, Domen RE. Coagulation and Immunology. Clin Lab Med 1986. [DOI: 10.1016/s0272-2712(18)30831-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
21
|
Abstract
A series of monoclonal antibodies have been produced which recognize different epitopes of the factor VIII molecule. The antibodies were raised in mice against high purity factor VIII (FVIII) and the mouse spleens used in cell fusion experiments. Following cell fusion the hybridoma supernatants were used for screening with a solid phase radioimmunoassay (RIA) technique. The antibodies detected were differentiated by their degree of attachment to 2 components of the FVIII molecule, FVIII related antigen (FVIIIR:Ag) (also called von Willebrand's Factor) and FVIII coagulant (FVIIIC). Immunofluorescence and immunoperoxidase studies both showed the FVIIIR:Ag antibodies to be localized to the endothelial cells of the blood vessel walls. They can, therefore, be used for histological identification of these cells on cryostat and paraffin sections. The anti-FVIIIR:Ag antibodies have no anticoagulant properties, whereas the anti-FVIIIC antibody reacts as an instant inhibitor with a strength of 35,000 new Oxford U/ml. These antibodies are stable reagents and suitable for radioimmunoassay for both FVIIIR:Ag and FVIIIC.
Collapse
|
22
|
|
23
|
|
24
|
Ghosh S, Rizza CR. Changes in the character of Factor VIII inhibitors following Factor VIII transfusion. SCANDINAVIAN JOURNAL OF HAEMATOLOGY 1984; 33:239-43. [PMID: 6438792 DOI: 10.1111/j.1600-0609.1984.tb02222.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Factor VIII inhibitors from 4 haemophiliacs have been studied at intervals following transfusion of a factor VIII preparation with an aim to correlate their reaction kinetic and avidity with their immuno-chemical character. Post-treatment antibodies are more avid than pre-treatment antibodies and show a second order reaction while pre-treatment antibodies produce a graph of complex nature for the time course inactivation of Factor VIII. It seems that IgG3 anti VIII:C that forms a significant part of post-treatment antibody is responsible for these discrepancies.
Collapse
|
25
|
|
26
|
Heisel MA, Gomperts ED, McComb JG, Hilgartner M. Use of activated prothrombin complex concentrate over multiple surgical episodes in a hemophilic child with an inhibitor. J Pediatr 1983; 102:951-4. [PMID: 6406656 DOI: 10.1016/s0022-3476(83)80032-8] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
27
|
Nanu A, Sood SK. Plasmapheresis in pediatric practice. Indian J Pediatr 1983; 50:105-11. [PMID: 6688605 DOI: 10.1007/bf02821427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
28
|
Rainsford SG, Aronstam A, Holborow EJ, McLellan DS. Anticoagulant antibodies in the synovial membranes of patients suffering from haemophilia, rheumatoid arthritis and other rheumatic disorders. J Clin Pathol 1982; 35:673-80. [PMID: 6806334 PMCID: PMC497748 DOI: 10.1136/jcp.35.6.673] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
This study has identified IgG and IgM anticoagulant antibodies in the synovial membranes of patients suffering from haemophilia and rheumatoid arthritis (RA) but not in synovial tissues from normal subjects or in patients with other arthritides. In the majority of cases the antibody appeared to have the specificity of the lupus-like anticoagulant (LLA) seen in patients with systemic lupus erythematosus (SLE). The importance of these findings with regard to the treatment of certain cases of haemophilia and RA and the possible relation between the presence of these antibodies and viral infections is discussed.
Collapse
|
29
|
Ly B, Michaelsen TE, Dahl O, Frøland SS. Characterization of an antibody to factor VIII in a patient with acquired hemophilia with circulating immune complexes. SCANDINAVIAN JOURNAL OF HAEMATOLOGY 1982; 28:132-40. [PMID: 6806894 DOI: 10.1111/j.1600-0609.1982.tb00505.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
A 73-year-old previously healthy woman was admitted because of severe bleeding from esophagitic lesions and intraabdominal bleeding following hysterectomy. Acquired hemophilia, probably due to an IgG antibody to factor VIII (64 inhibitor units/ml) was noticed, the VIII:C in the patient's plasma being 18% or normal. Immune complexes isolated by polyethylene glycol precipitation had only a weak factor VIII inhibiting activity whereas IgG purified from the complexes and monomeric IgG present in her plasma exerted a strong inhibition. Removal of the complexes from plasma had no effect on the inhibitor titer thus indicating that only a minor part of the antibody was circulating as immune complexes. Plasma or purified IgG from the patient decreased the VIII:C of normal plasma to 18 og 14%, respectively, total inhibition being impossible to achieve even in antibody excess, probably reflecting residual activity of factor VIII bound to the patient's antibodies. The ristocetin cofactor activity of normal plasma was unaffected by the antibodies. Transfusion of factor VIII concentrate to the patient resulted in therapeutic levels of circulating factor VIII and transfused factor VIII circulated longer than usual. Partial remission of the disease with adequate levels of VIII:C occurred after 3 months.
Collapse
|
30
|
LLoyd JV, Tunbridge LJ. Coagulation inhibitor in hypothyroidism. BMJ : BRITISH MEDICAL JOURNAL 1981; 283:500. [PMID: 6790035 PMCID: PMC1506242 DOI: 10.1136/bmj.283.6289.500-a] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
31
|
Joshua DE, Exner T, Holmes D, Rickard KA, Kronenberg H. Antibodies to human factor VIII complex from BALB/c mice. Thromb Res 1981; 22:345-52. [PMID: 6795746 DOI: 10.1016/0049-3848(81)90127-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
32
|
Wensley RT, Stevens RF, Burn AM, Delamore IW. Plasma exchange and human factor VIII concentrate in managing haemophilia A with factor VIII inhibitors. BRITISH MEDICAL JOURNAL 1980; 281:1388-9. [PMID: 6777018 PMCID: PMC1715018 DOI: 10.1136/bmj.281.6252.1388] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Plasma exchanges were combined with human factor VIII concentrate therapy in the treatment of major bleeding episodes in five patients with haemophilia A and factor VIII inhibitors. All patients had a good clinical response to combined treatment. Inhibitor levels showed satisfactory falls before rapid secondary increases of inhibitor levels took place. A sixth patient with von Willebrand's disease and a factor VIII clotting activity inhibitor was successfully prepared for operation using plasma exchange. Postoperative haemostasis and healing were normal. In two patients the plasma exchanges were relatively more effective than the administered human factor VIII in reducing the levels of factor VIII inhibitor. Combined plasma exchange and human factor VIII treatment may offer a rapidly effective means of reducing factor VIII inhibitor levels in this group of patients, together with significant saving of costs.
Collapse
|
33
|
Abstract
An immunoadsorbent was prepared by coupling rabbit and human antibodies against human factor VIII to Sepharose CL-2B. The resulting insoluble antibodies completely removed factor VIII and fibrinogen from normal human citrate plasma. Other coagulation factors were satisfactorily recovered in the eluted plasma. Following addition of fibrinogen, the factor VIII-deficient plasma was used for calibration of the one-stage factor VIII assay and compared with the hemophilic plasma. Parallel straight lines were obtained in the log-log plot against VIII:C, indicating that the artificial reagent can be used as a substitute for hemophilic plasma in determination of factor VIII procoagulant activity. The immunoadsorbent can be regenerated and repeatedly used for affinity chromatography binding of factor VIII.
Collapse
|
34
|
|
35
|
Mannucci PM, Federici A, Viganò S, Cattaneo M. Multiple dental extractions with a new prothrombin complex concentrate in two patients with factor VIII inhibitors. Thromb Res 1979; 15:359-64. [PMID: 494151 DOI: 10.1016/0049-3848(79)90143-9] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
36
|
Abstract
The hemophiliac knows when he is bleeding. When such a patient is aware of bleeding and consults a primary care physician, the episode usually has been of sufficient duration and is severe enough to demand prompt treatment with high-potency materials. Needless delay results in further complications and additional costly treatment. The type of deficiency can usually be ascertained from the patient or family member. If there is no history of an inhibitor, replacement therapy should be initiated promptly.
Collapse
|
37
|
Parry DH, Bloom AL. Failure of factor VIII inhibitor bypassing activity (Feiba) to secure haemostasis in haemophilic patients with antibodies. J Clin Pathol 1978; 31:1102-5. [PMID: 739057 PMCID: PMC1145493 DOI: 10.1136/jcp.31.11.1102] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Factor IX concentrates have been widely advocated in the treatment of haemophilic patients with factor VIII inhibitors. Five such patients were given the 'activated' factor IX concentrate--factor VIII inhibitor bypassing activity (Feiba)--for 14 separate bleeding episodes. In six of the episodes, including two with external blood loss, bleeding progressed in spite of treatment. In none of the other eight episodes was there a prompt response, and it was not possible to ascribe a definite therapeutic effect.
Collapse
|
38
|
|
39
|
Hintz G. [Current aspects on evaluation of assays of factor-VIII activity, factor-VIII associated protein and factor-VIII neutralizing antibody (author's transl)]. BLUT 1978; 36:95-107. [PMID: 638264 DOI: 10.1007/bf00996836] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
In evaluating factor-VIII activity it should be noted that regarding the remaining activity of deficient plasma a linear reference curve is achieved. In the standard population factor-VIII activity and factor-VIII associated protein are distributed approximately lognormally. Due to this distribution certain results have been gained for the optimal choice of localisation and dispersion measures. It is assumed that the proportions of neutralized factor-VIII activity in plasma are distributed according to Poisson. The applicability of the Poisson distribution was also proved for the free factor-VIII activity portion. Due to the Poisson distribution the antibody unit is clearly defined, thus eliminating a further discussion on the establishment of an arbitrary standardized antibody unit.
Collapse
|
40
|
Michiels JJ, Bosch LJ, van der Plas PM, Abels J. Factor VIII inhibitor postpartum. SCANDINAVIAN JOURNAL OF HAEMATOLOGY 1978; 20:97-107. [PMID: 305611 DOI: 10.1111/j.1600-0609.1978.tb02434.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Acquired factor VIII deficiency in women postpartum due to a factor VIII inhibitor is rare and the etiology is unknown. In this study a case report and a review of the literature are given. The haemorrhagic diathesis resembles classic haemophilia, with the exception that ecchymoses and tissue bleeding occur more frequently. The potency of the inhibitor may vary from weak to strong and the inactivation of factor VIII coagulant activity (factor VIII-C) by the inhibitor is of a non-linear type. Severe bleeding has been fatal in a few cases, but factor VIII concentrate substitution has usually been successful without anamnestic response of inhibitor activity. There is no convincing evidence that immunosuppression is effective, also because the natural history of the disease is characterised by a spontaneous disappearance of the factor VIII-C inhibitor. Treatment of bleeding symptoms with factor VIII concentrate should therefore not be reserved for life threatening haemorrhages only.
Collapse
|
41
|
Preston FE, Dinsdale RC, Sutcliffe DJ, Bardhan G, Wyld PJ, Hamlyn JF. Factor VIII inhibitor by-passing activity (FEIBA) in the management of patients with factor VIII inhibitors. Thromb Res 1977; 11:643-51. [PMID: 929513 DOI: 10.1016/0049-3848(77)90022-6] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
42
|
Abstract
The evaluation of the bleeding patient starts with the integration of data from the history and physical examination. From this results either one probable explanation that can easily be substatniated by laboratory studies or, as more commonly occurs in practice, several possibilities that are reasonable and must be investigated by more extensive laboratory tests. In either event, the initial laboratory evaluation usually includes examination of the peripheral blood and measurement of the platelet count, bleeding time, prothrombin time, partial thromboplastin time, and thrombin time. More specific laboratory tests are then performed if indicated.
Collapse
|
43
|
Price DA, d'Souza S, Ekert H. The use of non-activated prothrombin concentrate in the management of haemophilia A with factor VIII antibodies. AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE 1977; 7:286-90. [PMID: 269689 DOI: 10.1111/j.1445-5994.1977.tb03688.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Three children with haemophilia and antibodies to factor VIII were treated with a non-activated prothrombin concentrate (Prothrombinex) for 12 bleeding episodes. There was clear clinical response and joint aspirations were performed after infusions of phothrombinex in a dose of 30--50 factor IX units/kg body weight and there was no clinical evidence of thrombosis or febrile reactions. There was a significant shortening of the activated partial thromboplastin time (PTT) at one and four hours after the initial infusion with a return to pre-infusion levels 9--24 hours after infusion. The shortening in the PTT was less marked in subsequent infusions. There were no changes in the level of factor VIII procoagulant activity, factor VIII related antigen or factor VIII antibodies after the infusion. In two patients platelet function studies were unaltered by the infusion and in one patient procoagulant levels of factor II, IX and X were no greater than expected from the infusion. We conclude that infusions of non-activated prothrombin concentrates are clinically effective in the treatment of children with haemophilia and factor VIII antibodies but the mechanism of action is unknown.
Collapse
|
44
|
|
45
|
Bird P, Rizza CR. A method for detecting factor-VIII clotting activity associated with factor VIII-related antigen in agarose gels. Br J Haematol 1975; 31:5-12. [PMID: 1240008 DOI: 10.1111/j.1365-2141.1975.tb00826.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
A method for detecting factor-VIII clotting activity in agarose is described. It is based on factor VIII promoting coagulation in a mixture of haemophilic plasma in agarose which is detected by a change in opacity. When this test was used to detect factor-VIII clotting activity in a one-dimensional Laurell electroimmunoassay for factor VIII-related antigen all the factor-VIII activity was found in the same position as the factor VIII-related antigen immunoprecipitate. Factor-VIII clotting activity did not appear to be simply trapped in this immunoprecipitate and therefore it has been concluded that the molecule containing factor-VIII clotting activity carries factor VIII-related antigen determinants.
Collapse
|
46
|
Bird P. Coagulation in an agarose gel and its application to the detection and measurement of factor VIII antibodies. Br J Haematol 1975; 29:329-40. [PMID: 1191553 DOI: 10.1111/j.1365-2141.1975.tb01827.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Evidence has been presented that fibrin formation may be detected directly in agarose gels containing citrated plasma when they are treated with thrombin or calcium chloride. A new assay is described for haemophilic factor-VIII antibody based on inhibition of fibrin formation within an agarose gel containing normal plasma.
Collapse
|
47
|
Lazerson J. Clinical approach to molecular biology of factor VIII: heterogeneity of the molecule. Ann N Y Acad Sci 1975; 240:370-7. [PMID: 1053882 DOI: 10.1111/j.1749-6632.1975.tb53376.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
48
|
Lewis JH, Oskins PB. Treatment of the hemophiliac with anti-VIII. Ann N Y Acad Sci 1975; 240:407-11. [PMID: 1053885 DOI: 10.1111/j.1749-6632.1975.tb53381.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
49
|
|
50
|
Gruson R, Rizza CR. Factor VIII-related antigen in tissues detected by the indirect immunofluorescence technique. BLUT 1974; 29:241-9. [PMID: 4138697 DOI: 10.1007/bf01635545] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|